EMA Accepts Application for Dovato in Children with HIV
The European Medicines Agency has validated ViiV Healthcare's application to expand the use of Dovato to younger age groups.
The validation of the application by the European Medicines Agency (EMA) to expand the use of Dovato in children is an event that traditional media present in a boring regulatory wrapper. But I see here a multi-layered story about how ViiV Healthcare (dominated by GSK) is preparing to reshape the pediatric segment of HIV therapy using institutional levers and clinical data of a new quality.
The Essence: What Is Really Happening
On May 11, 2026, ViiV Healthcare announced that the EMA validated the marketing application for Dovato (dolutegravir/lamivudine, DTG/3TC) in younger age groups. Simultaneously, a similar application was submitted to the FDA. Formally, this is a technical step—validation merely means acceptance of documents for review. But in reality, it is the final chord of a multi-year strategy rooted in the Rome Action Plan for pediatric HIV.
The real essence lies in the patients' age. The current EMA approval for Dovato covers only adults and adolescents over 12 years weighing at least 40 kg. The new application lowers the bar to children weighing from 20 kg (for the current tablet form) and introduces a dispersible form for children from 3 months weighing from 6 kg. This is not just an "indication expansion" but a transformation of Dovato into a drug covering almost the entire life cycle of an HIV patient—from infancy to old age.
The clinical basis for the application is the phase 2/3 D3/Penta-21 study, sponsored by the PENTA Foundation with support from ViiV. It involves 370 children aged 2 to 15 years, randomized to a two-drug regimen of DTG/3TC versus standard triple therapy. And here lies the first non-obvious point: the study is still active, with an estimated completion date of September 30, 2026. ViiV is submitting the application based on interim safety and pharmacokinetic data, without waiting for final efficacy results. This is an aggressive regulatory move, possible only with high confidence in the outcome.
Timeline and Context
The path to this application has been paved by a decade of institutional work by ViiV in pediatric HIV. The company has consistently built an access architecture: 13 voluntary licensing agreements with generic manufacturers, an agreement with the Medicines Patent Pool (MPP) for pediatric formulations of abacavir, and the creation of the Paediatric Innovation Seed Fund. Approximately 3.4 million children live with HIV worldwide, and 72% of those in need of treatment lack access. This is not just a market—it is a humanitarian imperative backed by regulatory obligations.
Timeline of key events:
- July 1, 2019: EMA approves Dovato for adults.
- April 22, 2022: Start of the D3/Penta-21 study.
- April 8, 2026: ViiV announces collaboration with MPP on pediatric formulations.
- April 29, 2026: At CROI 2026 in Denver, ViiV presents data on ultra-long-acting regimens and pediatric studies.
- May 11, 2026: EMA validates the application; FDA accepts the NDA.
The context of CROI 2026 is particularly important. There, ViiV presented data on VH184—a third-generation integrase inhibitor with potential for dosing every 4 months. The pediatric application for Dovato is part of a broader strategy where INSTI regimens are positioned as a central element of treatment at all life stages.
Who Wins and Who Loses
ViiV Healthcare (and GSK) wins. The company gains a unique positioning: Dovato becomes the only two-drug INSTI regimen available for children from 3 months. This solidifies ViiV's status as a leader in pediatric HIV, directly translating into reputational capital and regulatory preferences for future applications. Additionally, pediatric exclusivity in the US provides an extra 6 months of patent protection.
Children with HIV and their families win. A two-drug regimen means lower cumulative drug exposure, which is critical for a growing body. The dispersible form solves the problem of swallowing pills for infants. Children receive INSTI therapy, which is considered more metabolically friendly than older regimens based on boosted protease inhibitors.
Merck loses. As we discussed in a previous analysis, Merck just received approval for Idvynso (doravirine/islatravir) for adults. But Merck has no pediatric strategy for this drug at such an advanced stage. ViiV is ahead of the competitor in a segment that is becoming key for long-term loyalty: a patient who starts therapy in childhood is highly likely to stay on the same drug class into adulthood.
An implicit loser: manufacturers of older pediatric formulations. The pediatric ARV market is fragmented, with many children receiving suboptimal regimens due to limited formulations. The shift to DTG/3TC in dispersible form will render many older regimens (especially those based on lopinavir/ritonavir) obsolete.
What the Media Isn't Saying
Mainstream coverage focuses on expanding access and the humanitarian mission. But no one writes that the EMA application validation is also a strategic response to regulatory pressure on pediatric obligations.
Every new drug in the EU must have an agreed Pediatric Investigation Plan (PIP), unless it receives a waiver or deferral. By submitting the application now, ViiV is fulfilling commitments made at the initial approval of Dovato. The EMA's Pediatric Committee (PDCO) has the power to impose sanctions for non-compliance with PIP, including fines and suspension of marketing authorization. The validation of the application is not just the company's goodwill but the closure of a regulatory debt.
A non-obvious insight concerns the data supporting the application. In the PENTA-21 study, children receive DTG/3TC as first-line therapy, not as a switch regimen. This means ViiV is targeting not only the niche of therapy replacement but also treatment-naive patients—a segment that is much larger in pediatrics than in adults, since most children are just starting treatment.
A second insight is the connection to ultra-long-acting regimens. At CROI 2026, ViiV presented data from IMPAACT 2017 and IMPAACT 2036—studies of long-acting strategies in young patients. Dovato for children is a bridge to the future: children stabilized on oral DTG/3TC will become candidates for injectable ultra-long-acting regimens once they receive pediatric approval. ViiV is building a vertical funnel: from a dispersible tablet at 3 months to an injection every 4 months in adolescence.
Forecast: The Next 30 Days and 90 Days
30 days (by June 13, 2026):
Public discussion of the application will begin in professional communities. Pediatric HIV specialists will analyze the available PENTA-21 data. A key moment is the WHO's reaction. Dolutegravir is already recommended by WHO as a preferred first-line drug for children, but a formal recommendation of the two-drug regimen DTG/3TC for pediatrics could accelerate inclusion in national guidelines of countries in Africa and Southeast Asia, where the majority of pediatric patients are concentrated.
90 days (by August 13, 2026):
An FDA decision on the NDA is expected, as applications in the US and EU were submitted simultaneously. The FDA often acts faster than the EMA on pediatric matters. If the FDA grants approval by the end of summer, it will set a precedent for an accelerated EMA decision. Simultaneously, ViiV's generic partners through MPP will ramp up—they will need time to prepare dispersible formulations for low-income markets.
A critical trigger is the publication of 96-week data from PENTA-21. If by September 2026 the first results from the extended follow-up phase confirm sustained viral suppression in children, it will remove the last regulatory doubts. But the main long-term effect of this application is the normalization of the two-drug therapy concept for pediatrics. In 3-5 years, we will see other manufacturers (primarily Merck and Gilead) try to replicate this model, but ViiV will have a head start in real clinical experience and established physician loyalty. The pediatric HIV market, long a periphery of pharmaceutical strategies, is becoming a battlefield of giants, and ViiV has just taken the high ground.
— Editorial Team
